A human monoclonal antibody blocking SARS-CoV-2 infection
2020 · Nature Communications · 1,150 citations
https://doi.org/10.1038/s41467-020-16256-y
B
Berend‐Jan Bosch
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
202
Papers
23.4K
Citations
71
h-index
133
i10-index
Berend‐Jan Bosch is an academic researcher from Utrecht University. The author has contributed to research in topics: SARS-CoV-2 and COVID-19 Research & Animal Virus Infections Studies & Viral gastroenteritis research and epidemiology. The author has an h-index of 71, co-authored 172 publications.
ORCID: 0000-0002-3864-232XPapers by this author
worksMiddle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
2013 · The Lancet Infectious Diseases · 736 citations
https://doi.org/10.1016/s1473-3099(13)70164-6
SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells
2005 · Journal of Biological Chemistry · 386 citations
https://doi.org/10.1074/jbc.m508381200
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
2021 · Nature Communications · 204 citations
https://doi.org/10.1038/s41467-021-21968-w
Murine Coronavirus with an Extended Host Range Uses Heparan Sulfate as an Entry Receptor
2005 · Journal of Virology · 133 citations
https://doi.org/10.1128/jvi.79.22.14451-14456.2005
SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms
2021 · Nature Communications · 105 citations
https://doi.org/10.1038/s41467-021-25949-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat